Recent Updates
Recently added Catalysts
SIBN Positive Sentiment Score: 70/100

SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

Key Takeaway: SI-BONE, Inc. will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, in New York. The company's management will host a fireside chat at 11:00 a.m. ET, allowing investors to learn more about their technologies for sacropelvic disorders. SI-BONE has established itself as a leader in minimally invasive surgical solutions, having aided numerous surgeries since its inception in 2009. Interested parties can register for the livestream or access the archived session post-event.

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE has a strong track record of innovation in sacropelvic surgery.
  • The company has supported over 4,000 surgeons and performed over 110,000 procedures.
  • The upcoming conference presents an opportunity for investor engagement and visibility.

Full Press Release Details

SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.
Investors interested in listening to the conference call may do so by registering at this link: https://event.webcasts.com/starthere.jsp?ei=1696941&tp_key=589204a98b. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for the surgical treatment of sacropelvic disorders. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 4,000 surgeons in performing more than 110,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 140 peer-reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
Investor Contact: Saqib Iqbal investors@si-bone.com

Frequently Asked Questions

When is SI-BONE's fireside chat at the conference?

The fireside chat is on December 4, 2024, at 11:00 a.m. ET.

How can I listen to the SI-BONE conference call?

Investors can register to listen at the provided link.

Where can I find the archived webcast of the event?

The archived webcast will be available on SI-BONE's website for 90 days.

What does SI-BONE specialize in?

SI-BONE specializes in surgical treatment for sacropelvic disorders.

How many procedures has SI-BONE supported?

SI-BONE has supported over 110,000 sacropelvic procedures.

Last updated: Nov 20, 2024